Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (3) ·
Agomelatine (1) ·
Amoxapine (1) ·
Buprenorphine (1) ·
Butorphanol (1) ·
Clomipramine (1) ·
Codeine (2) ·
Desipramine (1) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Duloxetine (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Levorphanol (1) ·
Maprotiline (1) ·
Meperidine (1) ·
Methadone (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nalbuphine (1) ·
Nefazodone (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Phenelzine (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Tapentadol (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1)
brand:
None (6) ·
(multiple, generic dominant) (1) ·
Anafranil (1) ·
Aurorix (1) ·
Caplyta (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Dolophine (1) ·
Duragesic (1) ·
Edronax (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Parnate (1) ·
Rexulti (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Stadol (1) ·
Suboxone (1) ·
Surmontil (1) ·
Talwin (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vicodin (1) ·
Vivactil (1) ·
Vraylar (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Irreversible non-selective MAO inhibitor (3) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (35) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)
starting dose:
None (35) ·
25 mg (1) ·
42 mg PO once daily with food (no titration) (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
preparations:
None (35) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) ·
1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
42 mg capsules (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
onset:
None (34) ·
30–60 min (PO) (1) ·
Antipsychotic effect over weeks (1) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) ·
Weeks for psychosis/mood efficacy (1)
duration:
halflife:
None (34) ·
2.5–3 hours (1) ·
Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) ·
~12 hours (1) ·
~18 hours (terminal) (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~91 hours (1)
bioavailability:
pregnancy:
None (34) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Limited data (1) ·
Limited data; National Pregnancy Registry available (1) ·
Limited data; National Pregnancy Registry for Atypical Antipsychotics (1)
Showing below up to 40 results in range #1 to #40.